Table 1.

Characteristics of the analysed cohorts with primary Sjögren’s syndrome (pSS) and healthy controls

	Discovery cohort 1		Replication cohort 2
	Patients with pSS (n=17)	Controls (n=15)	Patients with pSS (n=27)	Controls (n=12)
Age, mean±SD years	56.4±16	60.8±16.5	64.2±13.4	65.6±16.9
Female sex (%)	100	100	100	100
Negative anti-SSA and anti-SSB (%)	7 (41.2%)	100	6 (22.2%)	100
Positive anti-SSA (%)	10 (58.8%)	–	21 (77.8%)	–
Positive anti-SSA and anti-SSB (%)	5 (29.4%)	–	14 (51.9%)	–
ESSDAI, mean±SD (range)	3.8±8.2 (0–19)	–	6.4±7.2 (0–29)	–
Treatments
Methotrexate (15 mg/week) (%)	2 (11.7%)	–	3 (11.1%)	–
Hydroxychloroquine (400 mg/day) (%)	5 (29.4%)	–	9 (33.3%)	–

ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index.